Biologics and Pregnancy: Insights From the OTIS Study

“Firm conclusions await the accumulation of target sample size for adalimumab and etanercept and multivariate analysis.

“It is important to recognize that many differences between medication-exposed and comparison groups can be accounted for by other maternal risk factors, and so until these are addressed in multivariate analysis, we are dealing with very preliminary results. We also will be evaluating minor anomalies, 1-year growth, and developmental screening data,” Dr. Chambers said.

'Firm conclusions await the accumulation of target sample size' needed for multivariate analysis.

Source DR. CHAMBERS